Also known as SL-401, Elzonris
Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).